Abstract
Background We aimed to explore whether children in hospital care with COVID-19 have increased post-discharge health care use when compared to children in hospital care with 1) RSV infection, and 2) other RTIs.
Methods In 34,214 children aged 1 month to 5 years who were registered with one or more hospital contacts with COVID-19 (N=128), RSV infection (N=4,009) or other RTIs (upper- and lower unspecified RTI as well as influenza) (N=34,457) (January 1st, 2017 to September 20th, 2021), we used a pre-post study design to investigate the individual all-cause primary and specialist health care use from 12 weeks prior to hospital admission, to 12 weeks after hospital discharge, stratified on infants (1-12 months) and toddlers (1-5 years).
Findings We found a slight increase in primary health care use in the first four weeks after discharge for children aged 1-12 months with COVID-19 when compared to children with RSV infection (0.064 percentage points, 95% CI 0.02-0.126, 0.52% relative increase). For children aged 1-5 years, COVID-19 discharge was associated with a 1-4 weeks increase in primary health care use when compared to children with RSV infection (0.068 percentage points, 95% CI 0.022-0.144, 0.53% relative increase) and other RTI (0.046 percentage points, 95% CI 0.002-0.091, 0.45% relative increase). For children aged 1-12 months in hospital care with COVID-19, we found a similar-magnitude-increase in post-discharge inpatient specialist care use, which lasted for 12 weeks.
Interpretation Our findings imply no severe impact on health care use after hospitalization with COVID-19 compared to hospitalization with RSV infection or other RTIs. The etiological mechanisms for potentially worse post-hospitalization complaints or health-seeking behavior for COVID-19 than for other RTIs in children should be further explored.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was internally funded by the Norwegian Institute of Public Health. No external funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The establishment of an emergency preparedness register forms part of the legally mandated responsibilities of The Norwegian Institute of Public Health (NIPH) during epidemics. Institutional board review was conducted, and The Ethics Committee of South-East Norway confirmed (June 4th, 2020, #153204) that external ethical board review was not required.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The individual-level data used in this study are not publicly available due to privacy laws, but the individual-level data in the registries compiled in Beredt C19 are accessible to authorized researchers after ethical approval and application to helsedata.no administered by the Norwegian Directorate of eHealth.
